Detection and Diagnosis of Pancreatic Cancer

胰腺癌的检测和诊断

• 批准号: 6915870
• 负责人: DAVID V GOLD
• 金额: $ 26.62万
• 依托单位: CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-09 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6915870
• 关键词: antigen antibody reaction; athymic mouse; biomarker; cell line; clinical research; diagnosis design /evaluation; early diagnosis; enzyme activity; glycosidases; glycosyltransferase; human tissue; immunocytochemistry; microarray technology; monoclonal antibody; mucins; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunology; oligosaccharides; pancreas neoplasms; posttranslational modifications; protein quantitation /detection; tumor antigens; xenotransplantation

DESCRIPTION (provided by applicant): Pancreatic cancer is one of the most insidious forms of cancer. Recent estimates of new cancer cases put pancreatic cancer at eighth and ninth among women and men, respectively. However, it is the fourth leading cause of all cancer deaths in both women and men, surpassed only by lung, colorectal, prostate, and breast cancers. Due largely to the location, and silent growth of the tumor, most patients present at a time when it is too late to undergo any realistic type of curative treatment. This has translated into a 5-year survival rate of less than 3%. In a recent report, "Pancreatic Cancer: An Agenda for Action", the NCI's Pancreatic cancer Progress Review Group drew specific attention to the urgent need for "better screening and diagnostic techniques" with a recommendation to "delineate and validate effective molecular biomarkers" for pancreatic cancer. With this in mind, we intend to develop and assess the utility of a PAM4, anti-MUC1 antibody-based immunoassay to detect, diagnose, and provide for the management of this disease. Although there have been several reports concerning anti-MUC1 MAbs reactive with several types of cancer, PAM4 appears to be unique, or nearly so, in terms of its specificity and the molecular characteristics of the epitope to which it is reactive. The long-term objective of this proposal is to identify specific biomarkers that can be combined with the PAM4 assay for enhanced diagnostic accuracy of pancreatic cancer. The specific aims of this proposal are Aim 1. To investigate the diagnostic accuracy of an immunoassay for the quantitation of PAM4-reactive MUC1 in biological fluids as a means for early detection and diagnosis of pancreatic cancer. Aim 2. To investigate the heterogeneity in expression of MUC1 epitope structures as a means to identify patterns that may be organ and/or tumor "specific/associated". Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses.

描述（由申请人提供）：胰腺癌是最阴险的癌症形式之一。最近对新癌症病例的估计分别使胰腺癌分别在男女中排名第八和第九。但是，这是男性和男性所有癌症死亡的第四个主要原因，仅被肺，结直肠，前列腺和乳腺癌超越。由于位置的位置和肿瘤的沉默生长，大多数患者在为时已晚，无法进行任何现实类型的治疗治疗。这已经转化为5年的生存率低于3％。在最近的一份报告“胰腺癌：动作议程”中，NCI的胰腺癌进度评论小组提出了对迫切需要“更好的筛查和诊断技术”的需求，并建议“划定和验证有效的有效分子生物标志物”对胰腺癌的措施。考虑到这一点，我们打算开发和评估PAM4，基于抗MUC1抗体的免疫测定的实用性，以检测，诊断和提供该疾病的治疗。尽管有几份有关抗MUC1 MAB反应多种类型癌症的报道，但就其特异性及其反应性表位的分子特征而言，PAM4似乎是独特的，或者几乎是如此。该提案的长期目标是确定可以与PAM4分析结合的特定生物标志物，以提高胰腺癌的诊断准确性。该提案的具体目的是目的1。研究免疫测定法对PAM4反应MUC1定量的诊断准确性，以作为胰腺癌的早期检测和诊断的一种手段。 目的2。研究MUC1表位结构表达的异质性，以此作为识别可能是器官和/或肿瘤“特定/相关”模式的手段。目的3。调查包含其他粘蛋白生物标志物是否可以通过多元分析提高诊断准确性。